Ashfield launches commercial engagement model

Amy Schofield 21 February 2018

Ashfield, part of UDG Healthcare, has announced the launch of a pioneering new commercial model called The Ashfield Solution.

In response to global market trends, The Ashfield Solution is an agile, multi-channel engagement model underpinned by a field analytics engine. The proprietary solution addresses the challenges of pharmaceutical companies needing to maintain or improve return on investment (ROI).

Utilising the AshfieldGuide, a sales analytics and planning platform, it provides a more efficient and agile sales model with the capability to flex resources in ‘real-time’ in reaction to market events.

The new model helps pharmaceutical companies optimise their investment in light of margin pressure, loss of exclusivity, new product data and new market entrants including biosimilars.

It provides advanced analytics capabilities in response to curve modelling, segmentation techniques, mix modelling and geospatial optimisation. In addition, the commercial model delivers engagement optimisation and monthly reporting on ROI, call attainment and performance.

Jez Moulding, EVP of Ashfield and COO of UDG Healthcare, said: "Our focus with this new model is to empower its users to maximise sales efficiency and impact. The analytics allows us to develop an optimised resource mix that cannot be achieved through the traditional pharma sales model. We look forward to working with pharmaceutical companies in delivering The Ashfield Solution, helping them to solve their challenges by maximising their investment in their multi-channel resource."


Make a comment

To voice your opinion, please Log in or Register.

Pf Magazine

Your resource for news, features, interviews, careers and events in the pharma industry.

Click here for the latest issue and to subscribe.